Tonix Pharmaceuticals prices $4.5M public offering of common stock and warrants

Tonix Pharmaceuticals Holding Corp.

Offering comprises 9M shares, 9M Series A warrants (5-yr, $0.50 exercise), 9M Series B warrants (1-yr, $0.50); combined price $0.50 per unit.
Gross proceeds ~$4.5M; net proceeds for working capital, manufacturing & R&D facilities, and product acquisition/licensing.
Placement agents A.G.P./Alliance Global Partners and Brookline Capital Markets; 7.0% cash fee plus up to $100k expense reimbursement.
Closing expected on or about October 3, 2023, subject to customary closing conditions.
Directors and officers subject to 60-day lock-up on sale of securities post-closing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC (effective 2023-09-28).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC
Effective: 2023-09-28

Exact text from the filing

On September 28, 2023, the Company also entered into a placement agent agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC (the “Placement Agents”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $4.5 million (effective 2023-09-28).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $4.5 million
Effective: 2023-09-28

Exact text from the filing

On September 28, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001839882-23-026088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.